HomeCompareCDXC vs EPRT

CDXC vs EPRT: Dividend Comparison 2026

CDXC yields 25.41% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CDXC wins by $37.8K in total portfolio value
10 years
CDXC
CDXC
● Live price
25.41%
Share price
$7.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$101.2K
Annual income
$11,579.48
Full CDXC calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — CDXC vs EPRT

📍 CDXC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCDXCEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CDXC + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CDXC pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDXC
Annual income on $10K today (after 15% tax)
$2,160.10/yr
After 10yr DRIP, annual income (after tax)
$9,842.56/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $1,072.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDXC + EPRT for your $10,000?

CDXC: 50%EPRT: 50%
100% EPRT50/50100% CDXC
Portfolio after 10yr
$82.3K
Annual income
$12,210.10/yr
Blended yield
14.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CDXC
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Altman Z
11.8
Piotroski
5/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDXC buys
0
EPRT buys
0
No recent congressional trades found for CDXC or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCDXCEPRT
Forward yield25.41%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$101.2K$63.4K
Annual income after 10y$11,579.48$12,840.73
Total dividends collected$64.5K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: CDXC vs EPRT ($10,000, DRIP)

YearCDXC PortfolioCDXC Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$13,241$2,541.30$11,205$505.18+$2.0KCDXC
2$17,313$3,144.86$12,672$682.46+$4.6KCDXC
3$22,368$3,842.92$14,490$930.48+$7.9KCDXC
4$28,574$4,640.12$16,786$1,282.69+$11.8KCDXC
5$36,114$5,539.72$19,753$1,791.56+$16.4KCDXC
6$45,185$6,543.46$23,677$2,541.64+$21.5KCDXC
7$56,000$7,651.51$29,008$3,672.99+$27.0KCDXC
8$68,782$8,862.44$36,463$5,425.08+$32.3KCDXC
9$83,770$10,173.24$47,238$8,221.57+$36.5KCDXC
10$101,213$11,579.48$63,385$12,840.73+$37.8KCDXC

CDXC vs EPRT: Complete Analysis 2026

CDXCStock

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Full CDXC Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CDXC vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDXC vs SCHDCDXC vs JEPICDXC vs OCDXC vs KOCDXC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.